Cancer Research and Treatment10.4143/crt.2019.7262020523973-986RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast CancerTian-Hao Weng, Min-Ya Yao, Xiang-Ming Xu, Chen-Yu Hu, Shu-Hao Yao, Yi-Zhi Liu, Zhi-Gang Wu, Tao-Ming Tang, Pei-Fen Fu, Ming-Hai Wang, Hang-Ping Yao,,
Frontiers in Oncology10.3389/fonc.2019.0137720199Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic CancerChen-Yu Hu, Xiang-Ming Xu, Bo Hong, Zhi-Gang Wu, Yun Qian, Tian-Hao Weng, Yi-Zhi Liu, Tao-Ming Tang, Ming-Hai Wang, Hang-Ping Yao
British Journal of Pharmacology10.1111/bph.132112015172174228-4237Therapeutic targets of triple-negative breast cancer: a reviewVinayak S Jamdade, Nikunj Sethi, Nitin A Mundhe, Parveen Kumar, Mangala Lahkar, Neeraj Sinha,,
Breast Cancer Research10.1186/s13058-015-0524-02015171Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapyBetsy T Kren, Gretchen M Unger, Md J Abedin, Rachel I Vogel, Christine M Henzler, Khalil Ahmed, Janeen H Trembley,,,
Breast Cancer Research10.1186/bcr919200465New targets for therapy in breast cancer: Small molecule tyrosine kinase inhibitorsNancy U Lin, Eric P Winer,,
Current Breast Cancer Reports10.1007/s12609-015-0192-1201574215-223Potential Therapeutic Targets in Triple Negative Breast CancerHamdy A. Azim, Hatem A. Azim,,,
Tyrosine Kinases as Druggable Targets in Cancer10.5772/intechopen.860822019Noncoding RNAs as Predictive Biomarkers of Therapeutic Response to Tyrosine Kinase Inhibitors in Metastatic CancerJulia Kovacova, Ondrej Slaby
Cancer Cell International10.1186/s12935-018-0597-92018181B7-H4 overexpression contributes to poor prognosis and drug-resistance in triple-negative breast cancerLing Wang, Chao Yang, Xin-bo Liu, Li Wang, Fu-biao Kang,,
Breast Cancer Research10.1186/bcr32242012144Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of MetKelly L Mueller, Julie M Madden, Gina L Zoratti, Charlotte Kuperwasser, Karin List, Julie L Boerner,,
The Breast10.1016/j.breast.2017.01.006201736102Have all triple-negative breast cancer patients worse breast cancer-specific survival?Kadri Altundag,